Eimer Stahl represented an investment fund as well as certain of its principals and related entities, in a $22 million action arising out of the sale of NutraMax Products, Inc., a manufacturer of over-the-counter pharmaceuticals. The purchaser claimed that the partnership, other owners, and NutraMax’s management had misrepresented the prospects of its most significant supply agreement and presented inaccurate financial statements.  Eimer Stahl secured a motion to dismiss substantially all of plaintiffs’ claims, and subsequently obtained dismissal of an interlocutory appeal and denial of several further motions intended to revive the purchaser’s claims. 

Jump to Page

By using this site, you agree to our updated Terms of Use.